Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $47.18M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: 8286.79%
• EPS Growth: 87.23%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 0.89
• Shares Outstanding: 86,158,760
• 10 Day Avg. Volume: 1,246,964
• 30 Day Avg. Volume: 1,075,416
• PEG Ratio: -0.03
• Price to Book (P/B): 0.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.48
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.28
• 1Y Price Target: $4.67
• Price Target Upside: 749.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 44 Neutral
• Price Target: $0.50 ▼(-9.09%Downside)

The stock score is primarily impacted by the company's financial struggles and negative valuation metrics. Some technical indicators show neutral trends, but high beta suggests volatility. Recent corporate events provide mixed signals, with positive financial results but significant workforce reductions.

Positive Factors

Clinical Trials

Century Therapeutics is confident it should have a substantial update due to the momentum for CNTY-101 since dosing its first patient.

Innovative Platform

Analyst views the early preclinical data from the αβ iT platform as intriguing and believes clinical proof of concept from a functional iPSC-derived αβ iT candidate could be transformational for the company and the broader cell therapy space.

Negative Factors

Financial Position

Century's cash runway is only into the fourth quarter of the following year, which could limit investment in the company's innovative platform.

Price Target Reduction

The price target for Century Therapeutics was reduced due to a decrease in the peer group valuation component.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Century Therapeutics generates revenue through the development and commercialization of its proprietary cell therapy products. The company primarily focuses on clinical-stage therapies, which involve significant research and development investments. Revenue streams may include licensing agreements, partnerships with pharmaceutical companies, and potential future sales of approved therapies. Additionally, strategic collaborations with other biotech companies or institutions can provide funding and shared resources, contributing to Century Therapeutics' earnings. As the therapies advance through clinical trials and gain regulatory approval, commercial sales are expected to become a significant revenue source.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics is experiencing strong revenue growth, typical for the biotechnology sector, but is still operating at a net loss with significant operational inefficiencies. The balance sheet is robust with a good equity ratio and cash reserves, yet the company faces challenges in cash flow due to ongoing losses.

Income Statement

Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.

Balance Sheet

The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.

Cash Flow

Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.59M	2.23M	5.20M	0.00	0.00
Gross Profit	6.59M	2.23M	-4.87M	-4.58M	-1.75M
EBITDA	-111.47M	-121.21M	-119.34M	-89.92M	-51.44M
Net Income	-126.57M	-136.67M	-130.93M	-95.82M	-54.66M
Balance Sheet
Total Assets	353.22M	360.69M	486.54M	437.38M	106.78M
Cash, Cash Equivalents and Short-Term Investments	189.29M	172.74M	315.50M	222.88M	75.75M
Total Debt	53.83M	48.17M	49.41M	23.46M	21.55M
Total Liabilities	191.85M	175.94M	183.81M	41.14M	213.19M
Stockholders Equity	161.36M	184.75M	302.74M	396.24M	-106.41M
Cash Flow
Free Cash Flow	-110.29M	-102.08M	-16.55M	-133.97M	-51.09M
Operating Cash Flow	-110.14M	-88.35M	14.05M	-89.00M	-41.27M
Investing Cash Flow	47.48M	61.13M	-13.13M	-298.34M	-22.76M
Financing Cash Flow	74.56M	-9.72M	27.16M	417.77M	47.69M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 0.58, and below the 200-day MA of 0.83, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.88 is Neutral, neither overbought nor oversold. The STOCH value of 6.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CELU	56 Neutral	$78.55M	―	-232.51%	―	138.11%	76.60%
KRON	51 Neutral	$53.65M	―	-59.49%	―	21.15%	46.44%
Sector *	50 Neutral	AU$2.63B	3.88	-56.57%	2.69%	36.37%	13.78%
IPSC	44 Neutral	$47.18M	―	-10.49%	―	8286.79%	87.23%
PASG	44 Neutral	$20.03M	―	-83.73%	―	―	42.39%
STTK	42 Neutral	$36.48M	―	-71.90%	―	69.65%	27.98%
JSPR	35 Underperform	$43.26M	―	-101.34%	―	―	21.40%

Century Therapeutics Corporate Events

Century Therapeutics Announces Major Workforce Reduction

On July 1, 2025, Century Therapeutics‘ Board of Directors approved a significant reduction in force, cutting approximately 51% of its workforce to concentrate on high-potential programs. The company anticipates incurring around $3.7 million in severance and related costs, with the reduction expected to be largely completed by the end of the third quarter of 2025.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Holds 2025 Annual Stockholders Meeting

On June 12, 2025, Century Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, Daphne Quimi and Carlo Rizzuto, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP’s appointment as the company’s independent registered public accounting firm for the 2025 fiscal year was ratified. These decisions reflect the company’s ongoing efforts to strengthen its governance and ensure financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Reports Strong Q1 2025 Financial Results

On May 15, 2025, Century Therapeutics reported its first-quarter financial results and provided a business update. The company initiated patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in the U.S., with plans to expand to Europe. Century is also preparing to start IND-enabling studies for CNTY-308 in mid-2025. Financially, the company reported a net income of $76.6 million for the quarter, significantly up from a net loss in the same period last year, largely due to collaboration revenue from a terminated agreement with Bristol-Myers Squibb.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.